Zentalis Pharmaceuticals, Inc. (ZNTL) — Institutional Holders, Q2 2026 (page 2)

115 institutional investment managers reported a ZNTL position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $228.9M. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 101 to 115. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

ZNTL 13F holders ranked 101–115 of 115

Institutional investors reporting a position in Zentalis Pharmaceuticals, Inc. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Tower Research Capital (TRC)#101 · 3,115 sh$15.1K+174.7%
EverSource Wealth Advisors#102 · 1,944 sh$9.4K+143.9%
ROYAL BANK OF CANADA#103 · 1,636 sh$8.0K+1569.4%
Sterling Capital Management#104 · 1,008 sh$4.9KNew
Wilmington Savings Fund Society, FSB#105 · 1,000 sh$4.8K0.0%
SUMMIT SECURITIES GROUP#106 · 514 sh$2.5KNew
NISA INVESTMENT ADVISORS#107 · 387 sh$1.9K0.0%
Fortitude Family Office#108 · 209 sh$1.0K0.0%
HighMark Wealth Management#109 · 130 sh$630.000.0%
Silicon Valley Capital Partners#110 · 84 sh$407.000.0%
Caitong International Asset Management , Ltd#111 · 31 sh$150.00New
SBI Securities , Ltd.#112 · 27 sh$131.000.0%
Inspire Investing#113 · 21 sh$104.000.0%
Optiver Holding B.V.#114 · 4 sh$19.00-90.9%
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#115 · 689 sh—New

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.